Vivos Therapeutics Inc expected to post a loss of 61 cents a share - Earnings Preview

Reuters11-09

* Vivos Therapeutics Inc is expected to show a rise in quarterly revenue when it reports results on November 12 (estimated) for the period ending September 30 2024

* The Littleton Colorado-based company is expected to report a 23.0% increase in revenue to $4.061 million from $3.3 million a year ago, according to the estimate from one analyst, based on LSEG data.

* LSEG's mean analyst estimate for Vivos Therapeutics Inc is for a loss of 61 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Vivos Therapeutics Inc is $7.43, above its last closing price of $2.84.

This summary was machine generated November 8 at 22:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482845241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 06:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482845241","market":"us","top_or_hot":-1,"title":"Vivos Therapeutics Inc    expected to post a loss of 61 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* <a href=\"https://laohu8.com/S/VVOS\">Vivos Therapeutics</a> Inc     is expected to show a rise in quarterly revenue when it reports  results on November 12 (estimated) for the period ending September 30 2024</p><p>   * The Littleton Colorado-based  company is expected to report a 23.0% increase in revenue to $4.061 million from $3.3 million a year ago, according to the estimate from one analyst, based on LSEG data.</p><p>   * LSEG's mean analyst estimate for Vivos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is for a loss of 61 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Vivos Therapeutics Inc is $7.43, above its last closing price of $2.84. </p><p>This summary was machine generated November 8 at 22:22 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivos Therapeutics Inc    expected to post a loss of 61 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivos Therapeutics Inc    expected to post a loss of 61 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 06:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Vivos Therapeutics Inc     is expected to show a rise in quarterly revenue when it reports  results on November 12 (estimated) for the period ending September 30 2024   * The Littleton Colorado-...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VVOS","symbol_name":"Vivos Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2482845241","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482845241","pubTimestamp":1731104557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Vivos Therapeutics Inc     is expected to show a rise in quarterly revenue when it reports  results on November 12 (estimated) for the period ending September 30 2024   * The Littleton Colorado-base","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"VVOS":"Vivos Therapeutics"},"translate_title":"Vivos Therapeutics Inc预计每股亏损61美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VVOS":1},"content_text":"* Vivos Therapeutics Inc     is expected to show a rise in quarterly revenue when it reports  results on November 12 (estimated) for the period ending September 30 2024   * The Littleton Colorado-based  company is expected to report a 23.0% increase in revenue to $4.061 million from $3.3 million a year ago, according to the estimate from one analyst, based on LSEG data.   * LSEG's mean analyst estimate for Vivos Therapeutics Inc is for a loss of 61 cents per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Vivos Therapeutics Inc is $7.43, above its last closing price of $2.84. This summary was machine generated November 8 at 22:22 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482845241"}